Adaptimmune Therapeutics plc - American Depositary Shares (NQ:ADAP)

0.0549 UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 27, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Adaptimmune Therapeutics plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Earnings Scheduled For May 12, 2023 ↗

May 12, 2023

Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter.

Via Benzinga

Recap: Adaptimmune Therapeutics Q1 Earnings ↗

May 12, 2023

Via Benzinga

Adaptimmune Reports First Quarter Financial Results and Business Update

May 12, 2023

Completed submission of the clinical module (Part 2) of the afami-cel BLA; afami-cel is targeted to be the first marketed...

Via Newsfile

Earnings Preview For Adaptimmune Therapeutics ↗

May 11, 2023

Via Benzinga

Adaptimmune to Report Q1 2023 Financial and Business Updates on Friday, May 12, 2023

April 28, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - April 28, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell...

Via Newsfile

Adaptimmune Agrees To Merge With Another Cell Therapy Focused Company ↗

March 06, 2023

Via Benzinga

Adaptimmune Therapeutics's Earnings Outlook ↗

March 03, 2023

Via Benzinga

Expert Ratings for Adaptimmune Therapeutics ↗

January 05, 2023

Via Benzinga

Why Shares of Adaptimmune Therapeutics Jumped Tuesday ↗

April 11, 2023

The company bulks up its pipeline by regaining the rights to two of its clinical programs.

Via The Motley Fool

Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune

April 11, 2023

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy -- Adaptimmune and GSK will...

Via Newsfile

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Diffusion Pharmaceuticals Inc. (Nasdaq- DFFN), U.S. Xpress Enterprises, Inc. (NYSE – USX), TCR² Therapeutics Inc. (Nasdaq – TCRR), Costar Technologies, Inc. (OTC –

March 30, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason ↗

March 07, 2023

Via Benzinga

Why Is TCR2 Therapeutics Stock Trading Higher Today? ↗

March 06, 2023

TCR² Therapeutics (NASDAQ: TCRR) shares are trading higher on Monday after the company and Adaptimmune Therapeutics (NASDAQ: ADAP) announced an agreement under which the two companies will combine to...

Via Benzinga

Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 06, 2023

Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

March 06, 2023

Via Benzinga

TCR2 Therapeutics (NASDAQ: TCRR) and Adaptimmune Therapeutics (NASDAQ: ADAP) Announce Strategic Merger to Leverage Technologies and Create a New Major Cell Therapy Company

March 06, 2023

TCR2 Therapeutics, Inc. (NASDAQ: TCRR) operates as a clinical-stage immunotherapy company, which is focused on the research and development of

Via Spotlight Growth

Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today? ↗

March 06, 2023

A new deal offers a lifeline for TCRR stock and a compatible investment for Adaptimmune. Both companies are targeting solid cancer tumors.

Via InvestorPlace

ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders

March 06, 2023

From Halper Sadeh LLC

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

March 06, 2023

Via Benzinga

Adaptimmune Reports Fourth-Quarter and Full Year Financial Results and Business Update

March 06, 2023

BLA submission initiated for afami-cel, with aim to complete in mid-2023; afami-cel has the potential to be the first marketed...

Via Newsfile

Adaptimmune and TCR2 Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors

March 06, 2023

Compelling clinical data with clear paths to products and multiple near‐term value-creating catalystsComplementary technology platforms designed to treat solid tumors...

Via Newsfile

Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023

February 22, 2023

Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...

Via Newsfile

Adaptimmune Announces Changes to Board of Directors

February 16, 2023

Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - February 16, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in...

Via Newsfile

NXP Semiconductors, UBS Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

January 31, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Publication of Data from Adaptimmune's Completed Phase 1 Trial with Afami-cel in Nature Medicine Demonstrating an Acceptable Safety Profile and Encouraging Responses in Synovial Sarcoma

January 09, 2023

-The response rate was 44% in patients with late-stage, metastatic synovial sarcoma after a single dose of afami-cel --...

Via Newsfile

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 30, 2022

Via Benzinga

Adaptimmune Announces Initiation of Biologics License Application (BLA) Submission for Afami-cel, Its First-Gen Engineered TCR T-cell Therapy targeting MAGE-A4, For the Treatment of Synovial Sarcoma

December 23, 2022

- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial...

Via Newsfile

Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗

January 05, 2023

Via Benzinga

Credit Suisse, Autodesk And Other Big Losers From Wednesday ↗

November 25, 2022

U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Data from Cohort 1 of SPEARHEAD-1 Trial at CTOS Continue to Support BLA Submission for Afami-cel in Synovial Sarcoma - Response Rate and Durability Remain Consistent

November 18, 2022

- Data indicate continued clinical responses with an acceptable safety profile in heavily pre-treated patients with late-stage synovial sarcoma after...

Via Newsfile

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.